Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
Micardis(R) - Micardis Plus(R) - Effekte bei Zielorganschädigung (16 Abbildungen)
Übersicht


Zum ersten Bild Abb. 4: Telmisartan - Renoprotektiver Effekt Abb. 5: Telmisartan - Renoprotektiver Effekt Abb. 6: Telmisartan - Renoprotektiver Effekt Aktuelles Bild - Abb. 7: Telmisartan - Renoprotektiver Effekt Abb. 8: Telmisartan - Renoprotektiver Effekt Abb. 9: Telmisartan - Renoprotektiver Effekt Abb. 10: Telmisartan - LVH Zum letzten Bild
Abbildung 7: Telmisartan - Renoprotektiver Effekt
The Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study assessed the decline in renal function over 5 years in 250 patients with type 2 diabetes, mild-to-moderate hypertension, and GFR that was either normal or only mildly impaired.1 It employed a 1-month run-in period, followed by up-titration over a period of 1 month to either telmisartan 80 mg or enalapril 20 mg. Add-on antihypertensive therapy (- or -blocker, CCB, diuretic) was allowed after 2 months of double-blind treatment if seated DBP was >100 mmHg or SBP was >160 mmHg. There were no significant differences in GFR at 5 years, or in the change in GFR over 5 years. At endpoint, the difference (telmisartan minus enalapril) in GFR was –3.0 ml/min/1.73 m2, with 95% confidence interval –7.6 to +1.6. Telmisartan was comparable to enalapril (i.e. met the statistical test for non-inferiority), since the 95% confidence interval of the difference was <–10 mL/min/1.73 m2. 1. Barnett A, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351: 1952–1961.
 
Telmisartan - Renoprotektiver Effekt
Vorheriges Bild Nächstes Bild   


Abbildung 7: Telmisartan - Renoprotektiver Effekt
The Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study assessed the decline in renal function over 5 years in 250 patients with type 2 diabetes, mild-to-moderate hypertension, and GFR that was either normal or only mildly impaired.1 It employed a 1-month run-in period, followed by up-titration over a period of 1 month to either telmisartan 80 mg or enalapril 20 mg. Add-on antihypertensive therapy (- or -blocker, CCB, diuretic) was allowed after 2 months of double-blind treatment if seated DBP was >100 mmHg or SBP was >160 mmHg. There were no significant differences in GFR at 5 years, or in the change in GFR over 5 years. At endpoint, the difference (telmisartan minus enalapril) in GFR was –3.0 ml/min/1.73 m2, with 95% confidence interval –7.6 to +1.6. Telmisartan was comparable to enalapril (i.e. met the statistical test for non-inferiority), since the 95% confidence interval of the difference was <–10 mL/min/1.73 m2. 1. Barnett A, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351: 1952–1961.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung